P
Patrick G. Pilie
Researcher at University of Texas MD Anderson Cancer Center
Publications - 54
Citations - 2158
Patrick G. Pilie is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 14, co-authored 40 publications receiving 1034 citations. Previous affiliations of Patrick G. Pilie include University of Texas Health Science Center at Houston & University of Michigan.
Papers
More filters
Journal ArticleDOI
State-of-the-art strategies for targeting the DNA damage response in cancer
TL;DR: The authors review the progress made to date with PARP inhibitors, describe the expanding landscape of novel anticancer therapies targeting the DNA damage response and potential predictive biomarkers, mechanisms of resistance and combinatorial strategies are discussed.
Journal ArticleDOI
High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types.
Daniel J. McGrail,Patrick G. Pilie,Naim U. Rashid,Leonie Voorwerk,Maarten Slagter,Marleen Kok,Eric Jonasch,Mustafa Khasraw,Amy B. Heimberger,Bora Lim,NT Ueno,Jennifer K. Litton,Renata Ferrarotto,Jeffrey T. Chang,S. L. Moulder,Sy Lin +15 more
TL;DR: In this article, the authors compared approaches to determine TMB and identify the correlation between predicted neoantigen load and CD8 T cells, and found that TMB-H tumors exhibited a 39.8% ORR to ICB [95% confidence interval (CI) 34.9-44.8], which was significantly higher than that observed in low TMB (TMB-L) tumors.
Journal ArticleDOI
PARP Inhibitors: Extending Benefit Beyond BRCA-Mutant Cancers
TL;DR: Data that currently support clinical strategies for extending the benefit of PARP inhibitors beyond BRCA-mutant cancers, toward broader populations of patients through the use of novel biomarkers of homologous recombination repair deficiency (HRD), as well as predictive biomarkers rooted in mechanisms of sensitivity outside of HRD are discussed.
Journal ArticleDOI
Development of PARP and Immune-Checkpoint Inhibitor Combinations
TL;DR: In this review, the basic and translational science underpinning this promising new combination of PARP inhibition and programmed cell death 1(PD-1)/PD-L1-targeting antibodies represent a rationale combination.
Journal ArticleDOI
PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma.
Xian De Liu,Wen Kong,Wen Kong,Christine B. Peterson,Daniel J. McGrail,Anh Hoang,Xuesong Zhang,Truong Nguyen Anh Lam,Patrick G. Pilie,Haifeng Zhu,Kathryn E. Beckermann,Scott M. Haake,Sevinj Isgandrova,Margarita Martinez-Moczygemba,Nidhi Sahni,Nizar M. Tannir,Shiaw Yih Lin,W. Kimryn Rathmell,Eric Jonasch +18 more
TL;DR: It is shown that P BRM1 loss reduces IFNγ-mediated signalling resulting in a less immunogenic tumor microenvironment and that PBRM1 mutations correlate with lack of response to checkpoint inhibitor therapy in ccRCC patients.